| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|---|
| Litigation and opioid-related expenses, net | 17,974 | 11,524 | 16,765 | 14,485 |
| Depreciation | 128,128 | 121,815 | 112,712 | 107,940 |
| Acquisition-related deal and integration expenses | 52,838 | 99,380 | 38,712 | 25,758 |
| Amortization | 125,867 | 138,003 | 165,780 | 164,655 |
| Operating income | 867,654 | 1,036,190 | 706,254 | 672,476 |
| Other (income) loss, net | 110,417 | -3,546 | -57,874 | -12,814 |
| Interest expense, net | -81,794 | -103,988 | -27,933 | -31,328 |
| Income before income taxes | 896,277 | 928,656 | 620,447 | 628,334 |
| Income tax expense | 206,528 | 211,239 | 126,728 | 140,740 |
| Net income | 689,749 | 717,417 | 493,719 | 487,594 |
| Net income attributable to noncontrolling interests | 2,347 | -454 | 5,119 | 4,131 |
| Net income attributable to cencora, inc | 687,402 | 717,871 | 488,600 | 483,463 |
| Basic (in shares) | 193,822,000 | 193,796,000 | 193,758,000 | 198,260,000 |
| Basic (in usd per share) | 3.55 | 3.7 | 2.52 | 2.44 |
| Diluted (in shares) | 195,230,000 | 195,094,000 | 195,188,000 | 200,047,000 |
| Diluted (in usd per share) | 3.52 | 3.68 | 2.5 | 2.42 |
Cencora, Inc. (COR)
Cencora, Inc. (COR)